{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:26Z","timestamp":1788844226275,"version":"build-2803163510"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Monitoring children with 21-hydroxylase deficiency (21-OHD) requires suppression of adrenal androgen excess while avoiding glucocorticoid overtreatment. However, the clinical value of serum 11-oxygenated androgens beyond established biomarkers remains uncertain. We evaluated whether serum 11-ketotestosterone (11KT) is associated with overall disease-control status and whether it provides incremental information beyond androstenedione (A4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, single-center study of 67 children with classic 21-OHD and 67 healthy controls. Steroids were measured by liquid chromatography\u2013tandem mass spectrometry in fasting serum samples collected at 08:00 before medication. Two pediatric endocrinologists, masked to all steroid results, independently adjudicated overall disease-control status using clinical information from the preceding 12 months. Associations of 11KT with disease status and A4 were examined after adjustment for relevant covariates. Discrimination was assessed using receiver operating characteristic analysis, and the incremental value of 11KT beyond age, sex, Tanner group, and A4 was evaluated using bootstrap-corrected ridge regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum 11KT was higher in children with 21-OHD than in healthy controls (adjusted geometric mean ratio, 1.81; 95% CI, 1.24\u20132.64; P = 0.002) and in suboptimally controlled than in well-controlled children (6.17; 95% CI, 3.18\u201311.97; P &amp;lt; 0.001). Within the 21-OHD group, 11KT was strongly correlated with A4 after adjustment for age, sex, and Tanner group (partial r = 0.843). The single-marker area under the receiver operating characteristic curve (AUC) was 0.875 for 11KT and 0.906 for A4. Adding 11KT to a ridge model containing age, sex, Tanner group, and A4 changed the bootstrap-corrected AUC from 0.912 to 0.903 and the corrected calibration slope from 0.835 to 0.695. Lower-limit sensitivity analyses yielded the same qualitative findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Serum 11KT was associated with physician-adjudicated overall disease-control status in children with classic 21-OHD, but a single morning measurement provided no stable incremental information beyond A4 in this cohort. These findings do not support replacing A4 with 11KT or using 11KT as a standalone treatment target. Its potential clinical value may instead lie in contextual interpretation, particularly when conventional biomarkers and clinical findings are discordant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1913565","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:25:58Z","timestamp":1788841558000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum 11-ketotestosterone is associated with overall disease-control status but adds limited information beyond androstenedione in children with 21-hydroxylase deficiency"],"prefix":"10.3389","volume":"17","author":[{"given":"Tian","family":"Lan","sequence":"first","affiliation":[{"name":"Department of Genetics, Metabolism and Endocrinology, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Genetics, Metabolism and Endocrinology, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaibi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Genetics, Metabolism and Endocrinology, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Central Laboratory, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Genetics, Metabolism and Endocrinology, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Genetics, Metabolism and Endocrinology, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.2022-0009","article-title":"Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)","volume":"31","author":"Ishii","year":"2022","journal-title":"Clin Pediatr Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.10.7972","article-title":"Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: Is current replacement therapy satisfactory","volume":"86","author":"Charmandari","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa192","article-title":"11-Oxygenated androgens useful in the setting of discrepant conventional biomarkers in 21-hydroxylase deficiency","volume":"5","author":"Jha","year":"2021","journal-title":"J Endocr Soc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad134","article-title":"Interpretation of steroid biomarkers in 21-hydroxylase deficiency and their use in disease management","volume":"108","author":"Sarafoglou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-1181","article-title":"Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency","volume":"174","author":"Turcu","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3989","article-title":"11-Oxygenated androgens are biomarkers of adrenal volume and testicular adrenal rest tumors in 21-hydroxylase deficiency","volume":"102","author":"Turcu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2017.12.016","article-title":"Androgen excess is due to elevated 11-oxygenated androgens in treated children with congenital adrenal hyperplasia","volume":"178","author":"Kamrath","year":"2018","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1102741","article-title":"Monitoring treatment in pediatric patients with 21-hydroxylase deficiency","volume":"14","author":"Itonaga","year":"2023","journal-title":"Front Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ejendo\/lvae008","article-title":"Reference intervals for serum 11-oxygenated androgens in children","volume":"190","author":"Adriaansen","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105749","article-title":"Modelling adrenal steroid profiles to inform monitoring guidance in congenital adrenal hyperplasia","volume":"116","author":"Lawrence","year":"2025","journal-title":"eBioMedicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1774145","article-title":"Current insights into monitoring of congenital adrenal hyperplasia","volume":"17","author":"Leusink","year":"2026","journal-title":"Front Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.galenos.2020.2020.0091","article-title":"Traditional and new methods of bone age assessment - an overview","volume":"13","author":"Prokop-Piotrkowska","year":"2021","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1310.2009.07.003","article-title":"Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years","volume":"47","author":"Li","year":"2009","journal-title":"Chin J Pediatr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2021.105921","article-title":"11-oxygenated androgens and their relation to hypothalamus-pituitary-gonadal-axis disturbances in adults with congenital adrenal hyperplasia","volume":"212","author":"Auer","year":"2021","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1762815","article-title":"Characteristics of androgen metabolic pathways in patients with 21-hydroxylase deficiency and their association with disease control status","volume":"17","author":"Chong","year":"2026","journal-title":"Front Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.751191","article-title":"24-hour profiles of 11-oxygenated C19 steroids and Delta5-steroid sulfates during oral and continuous subcutaneous glucocorticoids in 21-hydroxylase deficiency","volume":"12","author":"Turcu","year":"2021","journal-title":"Front Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00031","article-title":"Measurement of salivary adrenal-specific androgens as biomarkers of therapy control in 21-hydroxylase deficiency","volume":"104","author":"Bacila","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14960","article-title":"Biomarkers in congenital adrenal hyperplasia","volume":"101","author":"Bacila","year":"2024","journal-title":"Clin Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1913565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:25:59Z","timestamp":1788841559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1913565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":19,"alternative-id":["10.3389\/fendo.2026.1913565"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1913565","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1913565"}}